ABK Biomedical Announces That its Eye90 Microspheres(R) Device Has Been Granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)

HALIFAX, NS, Dec. 5, 2023 -- (Healthcare Sales & Marketing Network) - ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces its Eye90 mi... Devices, Oncology, FDA ABK Biomedical, Eye90 microspheres, Hepatocellular Carcinoma, embolic therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news